2-(3-Chlorophenyl)-3-methylmorpholine | 1097796-78-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-(3-Chlorophenyl)-3-methylmorpholine
• CAS: 1097796-78-5
• 化学式: C₁₁H₁₄ClNO
• 分子量: 211.69
• InChiKey: BOFUZZAQNVYZFF-UHFFFAOYSA-N

物化性质

• 沸点：
  314.3±37.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] PHENYLMORPHOLINES AND ANALOGUES THEREOF<br/>[FR] PHÉNYLMORPHOLINES ET LEURS ANALOGUES
  申请人：RES TRIANGLE INST

  公开号：WO2011146850A1

  公开（公告）日：2011-11-24

  Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

  本文提供了化合物、前药及其制备方法，这些化合物和前药能够作为一种或多种单胺类神经递质的释放剂和/或摄取抑制剂，包括多巴胺、5-羟色胺和去甲肾上腺素。还提供了包含这些化合物或前药的药物组合物，该组合物可能进一步包含一种或多种额外的治疗剂。还提供了用于治疗各种可能对单胺类神经递质水平修改具有响应性的疾病的方法，例如早期肥胖、肥胖、成瘾和抑郁症。
• PHENYLMORPHOLINES AND ANALOGUES THEREOF
  申请人：Blough Bruce E.

  公开号：US20130203752A1

  公开（公告）日：2013-08-08

  Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

  本文提供了化合物和前药，以及制备这些化合物和前药的方法，这些化合物和前药能够作为单胺神经递质，包括多巴胺、血清素和去甲肾上腺素的释放剂和/或摄取抑制剂发挥作用。还提供了包含这些化合物或前药中的一个或多个的药物组合物，该组合物可能进一步包含一个或多个额外的治疗药物。还提供了治疗各种可能对单胺神经递质水平修正敏感的疾病的方法，例如肥胖前期、肥胖、成瘾和抑郁症。
• US9617229B2
  申请人：——

  公开号：US9617229B2

  公开（公告）日：2017-04-11